News

The agreement represents a significant initiative to undertake a large-scale approach to gene function analysis using shRNAi 'knock down' in genetically engineered mice as models for human biology.

The cash will come from agreements with new institutional investors in Australia, existing institutional investors in the US and a founding member of the Prana. As a result,

The approval decision follows a positive opinion issued by the European Medicines Agency. Lilly and Amylin anticipate launching Byetta in Europe in 2007. Byetta, also known as exenatide,

The broadened designation includes all types of acute hereditary angioedema (HAE) attacks. HAE is a rare and life-threatening inflammatory condition for which there is no approved therapy in

Orphan drug designation qualifies Repligen for seven years of exclusive marketing rights in the US. The designation also provides for benefit from certain tax credits and waives the

Santarus expects to receive a $15 million upfront license fee payable under the over-the-counter license agreement. Under the terms of the agreement, Schering-Plough will be responsible for the

The agreement requires Nippon Shinyaku to pay both royalties and milestone payments to Pharmion upon the achievement of certain regulatory and sales milestones, and also provides Nippon Shinyaku

The NPRL2 gene is believed to be important in the genesis of multiple types of cancer, including lung cancer and renal cell cancer. The gene is licensed to

Dupuytren's contracture is a disabling and recurring condition in which the joints in the hand contract, impairing patients' ability to straighten and move their fingers. The primary endpoint